KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...

Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P.

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...

Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemytm cell-free DNA technology. This revolutionary technology represents a significant ...

Audiencerate, an innovative technology company, leader in the development of advanced solutions for digital marketing (MarTech) and online advertising (AdTech) announces that it has signed a ...

2. DRI Healthcare Trust acquires royalty stake in Sebetralstat sales DRI Healthcare Trust, an affiliate of healthcare royalty PE firm DRI Capital, also announced in November that it acquired a ...

including KalVista Pharma's recently filed oral plasma kallikrein inhibitor sebetralstat. The lead investigator in the phase 2 trial, Danny Cohn of Amsterdam University Medical Center in the ...

has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to US$179 million ...